Cargando…
Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
Wolfram syndrome (WS), also known as a DIDMOAD (diabetes insipidus, early-onset diabetes mellitus, optic nerve atrophy and deafness) is a rare autosomal disorder caused by mutations in the Wolframin1 (WFS1) gene. Previous studies have revealed that glucagon-like peptide-1 receptor agonist (GLP1 RA)...
Autores principales: | Jagomäe, Toomas, Seppa, Kadri, Reimets, Riin, Pastak, Marko, Plaas, Mihkel, Hickey, Miriam A., Kukker, Kaia Grete, Moons, Lieve, De Groef, Lies, Vasar, Eero, Kaasik, Allen, Terasmaa, Anton, Plaas, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623088/ https://www.ncbi.nlm.nih.gov/pubmed/34831417 http://dx.doi.org/10.3390/cells10113193 |
Ejemplares similares
-
Liraglutide, 7,8-DHF and their co-treatment prevents loss of vision and cognitive decline in a Wolfram syndrome rat model
por: Seppa, Kadri, et al.
Publicado: (2021) -
Treatment with the dual-incretin agonist DA-CH5 demonstrates potent therapeutic effect in a rat model of Wolfram Syndrome
por: Jagomäe, Toomas, et al.
Publicado: (2023) -
The Expression of RAAS Key Receptors, Agtr2 and Bdkrb1, Is Downregulated at an Early Stage in a Rat Model of Wolfram Syndrome
por: Punapart, Marite, et al.
Publicado: (2021) -
GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome
por: Seppa, Kadri, et al.
Publicado: (2019) -
Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome
por: Toots, Maarja, et al.
Publicado: (2018)